CJC 1295 vs Ipamorelin
A side-by-side research reference for CJC 1295 and Ipamorelin — mechanism of action, catalogue data, and the key studies behind each compound.
| Comparison | ||
|---|---|---|
| Compound class | Peptides · Injectable vial | Peptides · Injectable vial |
| Mechanism of action | GHRH analogue (29 amino acids) that binds pituitary GHRH receptors to expand the releasable GH pool. Without DAC it produces a sharp physiological pulse; with DAC it binds albumin for a 6–8 day half-life. | Selective pentapeptide ghrelin-receptor (GHS-R1a) agonist that triggers GH release from pituitary somatotrophs with minimal cortisol, prolactin, or ACTH activity. |
| Reference concentration | 10mg | 5mg |
| Research form | Injectable vial | Injectable vial |
Key studies on CJC 1295
Published literature for this compound is indexed on PubMed.
More comparisons
Research Use Only
All compounds referenced on this page are sold for in vitro laboratory research use only. Not for human consumption, medical use, or self-administration. Not evaluated by the FDA. This page is for research and informational purposes only.

